Skip to main content
PMC home page
Clinical Cardiology logoLink to Clinical Cardiology
. 2009 Feb 3;24(3):183–190. doi: 10.1002/clc.4960240303

Angiotensin receptor blockers: Evidence for preserving target organs

Peter Carson 1, Thomas Giles 2,✉, Michael Higginbotham 3, Norman Hollenberg 4, William Kannel 5, Helmy M Siragy 6
PMCID: PMC6654811  PMID: 11288962

Abstract

Hypertension is a major problem throughout the developed world. Although current antihypertensive treatment regimens reduce morbidity and mortality, patients are often noncompliant, and medications may not completely normalize blood pressure. As a result, current therapy frequently does not prevent or reverse the cardiovascular remodeling that often occurs when blood pressure is chronically elevated. Blockade of the renin‐angiotensin system (RAS) is effective in controlling hypertension and treating congestive heart failure. Both angiotensin‐converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) inhibit the activity of the RAS, but these two classes of antihypertensive medications have different mechanisms of action and different pharmacologic profiles. Angiotensin‐converting enzyme inhibitors block a single pathway in the production of angiotensin II (Ang II). In addition, angiotensin I is not the only substrate for ACE. The ACE inhibitors also block the degradation of bradykinin that may have potential benefits in cardiovascular disease. Bradykinin is, however, the presumed cause of cough associated with ACE inhibitor therapy. Data from clinical trials on ACE inhibitors serve to support the involvement of the RAS in the development of cardiovascular disease. Angiotensin receptor blockers act distally in the RAS to block the Ang II type 1 (AT1) receptor selectively. Thus, ARBs are more specific agents and avoid many side effects. Experimental and clinical trials have documented the efficacy of ARBs in preserving target‐organ function and reversing cardiovascular remodeling. In some instances, maximal benefit may be obtained with Ang II blockade using both ARBs and ACE inhibitors. This review describes clinical trials that document the efficacy of ARBs in protecting the myocardium, blood vessels, and renal vasculature.

Keywords: angiotensin‐converting enzyme, angiotensin receptor blockers, angiotensin receptor subtypes, heart failure, hypertension, myocardial hypertrophy, myocardial infarction

Full Text

The Full Text of this article is available as a PDF (1,005.1 KB).

References

  • 1. American Heart Association : 1999 Heart and Stroke Statistical Update. Dallas, Texas: American Heart Association, 1998. [Google Scholar]
  • 2. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure : The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997; 157: 2413–2446 [DOI] [PubMed] [Google Scholar]
  • 3. Shaw E, Anderson JG, Maloney M, Jay SJ, Fagan D: Factors associated with noncompliance of patients taking antihypertensive medications. Hospital Pharmacy 1995; 30: 201–207 [PubMed] [Google Scholar]
  • 4. Leenen FH: Intermittent blood pressure control: Potential consequences for outcome. Can J Cardiol 1999; 15 (suppl C): 13C–18C [PubMed] [Google Scholar]
  • 5. Gainer JV, Morrow JD, Loveland A, King DJ, Brown NJ: Effect of bradykinin‐receptor blockade on the response to angiotensin‐converting‐enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med 1998; 339: 1285–1292 [DOI] [PubMed] [Google Scholar]
  • 6. de Gasparo M, Levens N: Does blockade of angiotensin II receptors offer clinical benefits over inhibition of angiotensin‐converting enzyme? Pharmacol Toxicol 1998; 82: 257–271 [DOI] [PubMed] [Google Scholar]
  • 7. Martens JR, Reaves PY, Lu D, Katovich MJ, Berecek KH, Bishop SP, Raizada MK, Gelband CH: Prevention of renovascular and cardiac pathophysiological changes in hypertension by angiotensin II type 1 receptor antisense gene therapy. Proc Natl Acad Sci USA 1998; 95: 2664–2669 [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]
  • 8. Chung O, Unger T: Pharmacology of angiotensin receptors and AT1 receptor blockers. Basic Res Cardiol 1998; 93 (suppl 2): 15–23 [DOI] [PubMed] [Google Scholar]
  • 9. Wang Z‐Q, Millatt LJ, Heiderstadt NT, Siragy HM, Johns RA, Carey RM: Differential regulation of renal angiotensin subtype AT1A and AT2 receptor protein in rats with angiotensin‐dependent hypertension. Hypertension 1999; 33: 96–101 [DOI] [PubMed] [Google Scholar]
  • 10. Mukoyama M, Nakajima M, Horiuchi M, Sasamura H, Pratt RE, Dzau VJ: Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven‐transmembrane receptors. J Biol Chem 1993; 268: 24539–24542 [PubMed] [Google Scholar]
  • 11. de Gasparo M, Siragy HM: The AT2 receptor: Fact, fancy and fantasy. Regul Pept 1999; 81: 11–24 [DOI] [PubMed] [Google Scholar]
  • 12. Horiuchi M, Hayashida W, Kambe T, Yamada T, Dzau VJ: Angiotensin type 2 receptor dephosphorylates Bcl‐2 by activating mitogen‐activated protein kinase phosphatase‐1 and induces apoptosis. J Biol Chem 1997; 272: 19022–19026 [DOI] [PubMed] [Google Scholar]
  • 13. Masaki H, Kurihara T, Yamaki A, Inomata N, Nozawa Y, Mori Y, Murasawa S, Kizima K, Maruyama K, Horiuchi M, Dzau VJ, Takahashi H, Iwasaka T, Inada M, Matsubara H: Cardiac‐specific overexpression of angiotensin II AT2 receptor causes attenuated response to AT1 receptor‐mediated pressor and chronotropic effects. J Clin Invest 1998; 101: 527–535 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14. Burnier M, Brunner HR: Angiotensin II receptor antagonists in hypertension. Kidney Int 1998; 54 (suppl 68): S‐107–S‐111 [DOI] [PubMed] [Google Scholar]
  • 15. Mooser V, Nussberger J, Juillerat L, Burnier M, Waeber B, Bidiville J, Pauly N, Brunner HR: Reactive hyperreninemia is a major determinant of plasma angiotensin II during ACE inhibition. J Cardiovasc Pharmacol 1990; 15: 276–282 [DOI] [PubMed] [Google Scholar]
  • 16. Fukami H, Okunishi H, Miyazaki M: Chymase: Its pathophysiological roles and inhibitors. Current Pharmaceutical Design 1998; 4: 439–453 [PubMed] [Google Scholar]
  • 17. Nishimura H, Hoffmann S, Baltatu O, Sugimura K, Ganten D, Urata H: Angiotensin I converting enzyme and chymase in cardiovascular tissues. Kidney Intern Suppl 1996; 55: S18–S23 [PubMed] [Google Scholar]
  • 18. Hollenberg NK, Fisher NDL, Price DA: Pathways for angiotensin II generation in intact human tissue. Evidence from comparative pharmacological interruption of the renin system. Hypertension 1998; 32: 387–392 [DOI] [PubMed] [Google Scholar]
  • 19. Guidelines Subcommittee : 1999 World Health Organization‐International Society of Hypertension guidelines for the management of hypertension. J Hypertens 1999; 17: 151–183 [PubMed] [Google Scholar]
  • 20. Kannel WB, Wilson PWF, Silbershatz H, D'Agostino RB: Epidemiology of risk factor clustering in elevated blood pressure In Multiple Risk Factors in Cardiovascular Disease: Strategies of Prevention of Coronary Heart Disease, Cardiac Failure, and Stroke (Eds. Gotto AMJ, Lenfant C, Paoletti R, Catapano AL, Jackson AS.), pp. 325–333. Boston, Massachusetts: Kluwer Academic Publishers, 1998. [Google Scholar]
  • 21. Colucci WS, Braunwald E: Pathophysiology of heart failure In Heart Disease. A Textbook of Cardiovascular Medicine, 5th Ed. (Ed. Braunwald E.), pp. 394–420. Philadelphia: W.B. Saunders Company, 1997. [Google Scholar]
  • 22. Weber KT, Clark WA, Janicki JS, Shroff SG: Physiologic versus pathologic hypertrophy and the pressure‐overloaded myocardium. J Cardiovasc Pharmacol 1987; 10 (suppl 6): S37–S50 [PubMed] [Google Scholar]
  • 23. Schelling P, Fischer H, Ganten D: Angiotensin and cell growth: A link to cardiovascular hypertrophy? J Hypertens 1991; 9: 3–15 [PubMed] [Google Scholar]
  • 24. Sadoshima J, Izumo S: Molecular characterization of angiotensin II‐induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor subtype. Circ Res 1993; 73: 413–423 [DOI] [PubMed] [Google Scholar]
  • 25. Lijnen P, Petrov V: Renin‐angiotensin system, hypertrophy and gene expression in cardiac myocytes. J Mol Cell Cardiol 1999; 31: 949–970 [DOI] [PubMed] [Google Scholar]
  • 26. Schmieder RE, Martus P, Klingbeil A: Reversal of left ventricular hypertrophy in essential hypertension. A meta‐analysis of randomized double‐blind studies. J Am Med Assoc 1996; 275: 1507–1513 [PubMed] [Google Scholar]
  • 27. Dahlöf B, Pennert K, Hansson L: Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. Am J Hypertens 1992; 5: 95–110 [DOI] [PubMed] [Google Scholar]
  • 28. Levy D, Salomon M, D'Agostino RB, Belanger AJ, Kannel WB: Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation 1994; 90: 1786–1793 [DOI] [PubMed] [Google Scholar]
  • 29. Thürmann PA, Kenedi P, Schmidt A, Harder S, Rietbrock N: Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension. Circulation 1998; 98: 2037–2042 [DOI] [PubMed] [Google Scholar]
  • 30. Breisch EA, White FC, Bloor CM: Myocardial characteristics of pressure overload hypertrophy. A structural and functional study. Lab Invest 1984; 51: 333–342 [PubMed] [Google Scholar]
  • 31. Sabbah HN, Sharov VG, Lesch M, Goldstein S: Progression of heart failure: A role for interstitial fibrosis. Mol Cell Biochem 1995; 147: 29–34 [DOI] [PubMed] [Google Scholar]
  • 32. Liu P, Sole MJ: What is the relevance of apoptosis to the myocardium? Can J Cardiol 1999; 15 (suppl B): 8B–10B [PubMed] [Google Scholar]
  • 33. Benedict CR, Johnstone DE, Weiner DH, Bourassa MG, Bittner V, Kay R, Kirlin P, Greenberg B, Kohn RM, Nicklas JM: Relation of neurohumoral activation to clinical variables and degree of ventricular dysfunction: A report from the Registry of Studies of Left Ventricular Dysfunction. SOLVD Investigators. J Am Coll Cardiol 1994; 23: 1410–1420 [DOI] [PubMed] [Google Scholar]
  • 34. Benedict CR, Shelton B, Johnstone DE, Francis G, Greenberg B, Konstam M, Probstfield JL, Yusuf S: Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. SOLVD Investigators. Circulation 1996; 94: 690–697 [DOI] [PubMed] [Google Scholar]
  • 35. The SOLVD Investigators : Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293–302 [DOI] [PubMed] [Google Scholar]
  • 36. The SOLVED Investigators : Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327: 685–691 [DOI] [PubMed] [Google Scholar]
  • 37. Crozier I, Ikram H, Awan N, Cleland J, Stephen N, Dickstein K, Frey M, Young J, Klinger G, Makris L, Rucinska E, for the Losartan Hemodynamic Study Group : Losartan in heart failure. Hemodynamic effects and tolerability. Circulation 1995; 91: 691–697 [DOI] [PubMed] [Google Scholar]
  • 38. Mazayev VP, Fomina IG, Kazakov EN, Sulimov VA, Zvereva TV, Lyusov VA, Orlov VA, Olbinskaya LI, Bolshakova TD, Sullivan J, Spormann DO: Valsartan in heart failure patients previously untreated with an ACE inhibitor. Int J Cardiol 1998; 65: 239–246 [DOI] [PubMed] [Google Scholar]
  • 39. Havranek EP, Thomas I, Smith WB, Ponce GA, Bilsker M, Munger MA, Wolf RA, for the Irbesartan Heart Failure Group : Dose‐related beneficial long‐term hemodynamic and clinical efficacy of irbesartan in heart failure. J Am Coll Cardiol 1999; 33: 1174–1181 [DOI] [PubMed] [Google Scholar]
  • 40. Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, Deedwania PC, Ney DE, Snavely DB, Chang PI, on behalf of Elite Study Investigators : Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997; 349: 747–752 [DOI] [PubMed] [Google Scholar]
  • 41. Urata H, Healy B, Stewart RW, Bumpus FM, Husain A: Angiotensin II‐forming pathways in normal and failing human hearts. Circ Res 1990; 66: 883–890 [DOI] [PubMed] [Google Scholar]
  • 42. Krombach RS, Clair MJ, Hendrick JW, Houck WV, Zellner JL, Kribbs SB, Whitebread S, Mukherjee R, de Gasparo M, Spinale FG: Angiotensin converting enzyme inhibition, AT1 receptor inhibition, and combination therapy with pacing induced heart failure: Effects on left ventricular performance and regional blood flow patterns. Cardiovasc Res 1998; 38: 631–645 [DOI] [PubMed] [Google Scholar]
  • 43. Spinale FG, de Gasparo M, Whitebread S, Hebbar L, Clair MJ, Melton DM, Krombach RS, Mukherjee R, Iannini JP O S‐J: Modulation of the renin‐angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing‐induced heart failure. I. Effects on left ventricular performance and neurohormonal systems. Circulation 1997; 96: 2385–2396 [DOI] [PubMed] [Google Scholar]
  • 44. Baruch L, Anand I, Cohen IS, Ziesche S, Judd D, Cohn JN, for the Vasodilator Heart Failure Trial (V‐HeFT) Study Group : Augmented short‐ and long‐term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Circulation 1999; 99: 2658–2664 [DOI] [PubMed] [Google Scholar]
  • 45. Spinale FG, Mukherjee R, Iannini JP, Whitebread S, Hebbar L, Clair MJ, Melton DM, Cox MH, Thomas PB, de Gasparo M: Modulation of the renin‐angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing‐induced heart failure. II. Effects on myocyte contractile processes. Circulation 1997; 96: 2397–2406 [DOI] [PubMed] [Google Scholar]
  • 46. Hamroff G, Blaufarb I, Mancini D, Katz SD, Bijou R, Jondeau G, Olivari M‐T, Thomas S, LeJemtel TH: Angiotensin II‐receptor blockade further reduces afterload safely in patients maximally treated with angiotensin‐converting enzyme inhibitors for heart failure. J Cardiovasc Pharmacol 1997; 30: 533–536 [DOI] [PubMed] [Google Scholar]
  • 47. Hamroff G, Katz SD, Mancini D, Blaufarb I, Bijou R, Patel R, Jondeau G, Olivari M‐T, Thomas S, Le Jemtel TH: Addition of angiotensin II receptor blockade to maximal angiotensin‐converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure. Circulation 1999; 99: 990–992 [DOI] [PubMed] [Google Scholar]
  • 48. Amadi A, Ponikowski P, Coats AJ: Role of catecholamines and sympathetic activation as a risk factor for coronary artery disease. J Cardiovasc Risk 1995; 2: 222–228 [PubMed] [Google Scholar]
  • 49. Dargie HJ, Byrne J: Pathophysiological aspects of the renin‐angiotensin‐aldosterone system in acute myocardial infarction. J Cardiovasc Risk 1995; 2: 389–395 [DOI] [PubMed] [Google Scholar]
  • 50. O'Connor CM, Hathaway WR, Bates ER, Leimberger JD, Sigmon KN, Kereiakes DJ, George BS, Samaha JK, Abbottsmith CW, Candela RJ, Topol EJ, Califf RM: Clinical characteristics and long‐term outcome of patients in whom congestive heart failure develops after thrombolytic therapy for acute myocardial infarction: Development of a predictive model. Am Heart J 1997; 133: 663–673 [DOI] [PubMed] [Google Scholar]
  • 51. Pfeffer MA: The Survival and Ventricular Enlargement (SAVE) study: Rationale and perspective. Herz 1993; 18 (suppl 1): 430–435 [PubMed] [Google Scholar]
  • 52. St John Sutton M, Pfeffer MA, Plappert T, Rouleau JL, Moyé LA, Dagenais GR, Lamas GA, Klein M, Sussex B, Goldman S: Quantitative two‐dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril. Circulation 1994; 89: 68–75 [DOI] [PubMed] [Google Scholar]
  • 53. Rouleau J‐L, Packer M, Moyé L, de Champlain J, Bichet D, Klein M, Rouleau JR, Sussex B, Arnold JM, Sestier F, Parker JO, McEwan P, Bernstein V, Cuddy TE, Lamas G, Gottlieb SS, McCans J, Nadeau C, Delage F, Wun C‐CC, Pfeffer MA: Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: Effect of captopril. J Am Coll Cardiol 1994; 24: 583–591 [DOI] [PubMed] [Google Scholar]
  • 54. Køber L, Torp‐Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, Videbæk J, Cole DS, Auclert L, Pauly NC, Aliot E, Persson S, Camm AJ, for the Trandolapril Cardiac Evaluation (TRACE) Study Group : A clinical trial of the angiotensin‐converting‐enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995; 333: 1670–1676 [DOI] [PubMed] [Google Scholar]
  • 55. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators : Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821–828 [PubMed] [Google Scholar]
  • 56. Dickstein K, Kjekshus J, for the OPTIMAAL Study Group : Comparison of effects of losartan and captopril on mortality in patients after acute myocardial infarction: The OPTIMAAL trial design. Am J Cardiol 1999; 83: 477–481 [DOI] [PubMed] [Google Scholar]
  • 57. United States Renal Data System : Incidence and prevalence of ESRD In USRDS 999 Annual Data Report, pp. 25–38. Ann Arbor, Mich: United States Renal Data System, 1999. [Google Scholar]
  • 58. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE, Shulman NB, Stamler J: Blood pressure and end‐stage renal disease in men. N Engl J Med 1996; 334: 13–18 [DOI] [PubMed] [Google Scholar]
  • 59. Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG, King AJ, Klahr S, Massry SG, Seifter JL, for the Modification of Diet in Renal Disease (MDRD) Study Group : Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 1995; 123: 754–762 [DOI] [PubMed] [Google Scholar]
  • 60. Salvetti A, Mattei P, Sudano I: Renal protection and antihypertensive drugs: Current status. Drugs 1999; 57: 665–693 [DOI] [PubMed] [Google Scholar]
  • 61. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, for the Collaborative Study Group : The effect of angiotensin‐converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456–1462 [DOI] [PubMed] [Google Scholar]
  • 62. Muirhead N, Cheung R, Rodger W, Lewanczuk R, Pecher E, Botteri F, Oddou‐Stock P: Valsartan (Diovan™): Effect on microalbuminuria in patients with type II diabetes and nephropathy (abstr 872‐5). J Am Coll Cardiol 1999; 33 (2 suppl A ): 299A [PubMed] [Google Scholar]
  • 63. Siragy HM, Carey RM: Protective role of the angiotensin AT2 receptor in a renal wrap hypertension model. Hypertension 1999; 33: 1237–1242 [DOI] [PubMed] [Google Scholar]
  • 64. Siragy HM, Carey RM: The subtype 2 (AT2) angiotensin receptor mediates renal production of nitric oxide in conscious rats. J Clin Invest 1997; 100: 264–269 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65. Siragy HM, Carey RM: The subtype‐2 (AT2) angiotensin receptor regulates renal cyclic guanosine 3′, 5′‐monophosphate and AT1 receptor‐mediated prostaglandin E2 production in conscious rats. J Clin Invest 1996; 97: 1978–1982 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66. Siragy HM, Inagami T, Ichiki T, Carey RM: Sustained hypersensitivity to angiotensin II and its mechanism in mice lacking the subtype‐2 (AT2) angiotensin receptor. Proc Natl Acad Sci USA 1999; 96: 6506–6510 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67. Kirk JK: Angiotensin‐II receptor antagonists: Their place in therapy. Am Fam Physician 1999: 59 (11): 3140–3148 [PubMed] [Google Scholar]

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES